Current Psychiatry Reports

, Volume 4, Issue 4, pp 279–283

Suicidality in schizophrenia: A review of the evidence for risk factors and treatment options

  • Herbert Y. Meltzer
Article

Abstract

Suicide is a major contributor to the morbidity and mortality of schizophrenia, accounting for approximately 10% of deaths in these patients. The known risk factors for suicide in schizophrenia include prior suicide attempts, substance abuse, male sex, onset during first decade of illness, social isolation, depression, and feelings of hopelessness. There is significant evidence suggesting that clozapine reduces the suicide rate in patients with schizophrenia and schizoaffective disorder. Possible factors that lead to a decrease in suicidality with clozapine include the following: a direct antidepressant action, improved cognitive function and insight, diminished negative symptoms, reduced substance abuse, and improved compliance. These effects may converge or lessen feelings of hopelessness and more of its converse optimism. The International Suicide Prevention Trial (InterSePT) is a large prospective, 2-year randomized trial of the comparative effects of clozapine and olanzapine involving 980 patients at high risk for suicide in 11 countries in 56 sites. The study included complete freedom to augment these treatments if needed, blinded ratings, a blinded Suicide Monitoring Board, and equivalent clinical contact. The results support the superiority of clozapine over olanzapine to reduce the risk of suicidality and suggest its use should be considered for all patients with schizophrenia with high risk for suicide.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Allebeck P: Schizophrenia: a life-shortening disease. Schizophr Bull 1989, 15:81–89.PubMedGoogle Scholar
  2. 2.
    Satcher D: Surgeon General USPHS. Psychiatr News 2001, 26:1.Google Scholar
  3. 3.
    Singh BS: Suicide: the public health crisis of our time. Aust N Z J Med 1998, 28:295–300.PubMedGoogle Scholar
  4. 4.
    Mortensen PB, Juel K: Mortality and causes of death in first admitted schizophrenic patients. Br J Psychiatry 1993, 163:183–189.PubMedGoogle Scholar
  5. 5.
    Meltzer HY, Alphs L, Altamura AC, et al.: International suicide prevention trial (InterSePT): reduced suicidality in schizophrenia with clozapine treatment. Arch Gen Psychiatry 2002, In press. A good article.Google Scholar
  6. 6.
    Niskanen P, Lonnqvist S, Achte K: Schizophrenia and suicide. Psychiatr Fennica 1973:223–227.Google Scholar
  7. 7.
    Planansky K, Johnston R: The occurrence and characteristics of suicidal preoccupation and acts in schizophrenia. Acta Psychiatr Scand 1971, 47:473–483.PubMedGoogle Scholar
  8. 8.
    Caldwell CB, Gottesman II: Schizophrenia—a high-risk factor for suicide: clues to risk reduction. Suicide Life Threat Behav 1992, 22:479–493.PubMedGoogle Scholar
  9. 9.
    Black DW: Mortality in schizophrenia—the Iowa Record-Linkage Study: a comparison with general population mortality. Psychosomatics 1988, 29:55–60.PubMedGoogle Scholar
  10. 10.
    Cohen LJ, Test MA, Brown RL: Suicide and schizophrenia: data from a prospective community treatment study. Am J Psychiatry 1990, 147:602–607.PubMedGoogle Scholar
  11. 11.
    Axelsson R, Lagerkvist-Briggs M: Factors predicting suicide in psychotic patients. Eur Arch Psychiatry Clin Neurosci 1992, 241:259–266.PubMedCrossRefGoogle Scholar
  12. 12.
    Ettlinger R: Evaluation of suicide prevention after attempted suicide. Acta Psychiatr Scand 1975, 260(suppl):64–124.Google Scholar
  13. 13.
    Meltzer HY: Suicidality and clozapine. J Clin Psychiatry 1996, 14:13–15.Google Scholar
  14. 14.
    Yarden P: Observations on suicide in chronic schizophrenics. Compr Psychiatry 1974, 15:325–333.PubMedCrossRefGoogle Scholar
  15. 15.
    Heila H, Isometsa ET, Henriksson MM, et al.: Suicide and schizophrenia: a nationwide psychological autopsy study on age-and sex-specific clinical characteristics of 92 suicide victims with schizophrenia. Am J Psychiatry 1997, 154:1235–1242.PubMedGoogle Scholar
  16. 16.
    Drake RE, Cotton PG: Depression, hopelessness, and suicide in chronic schizophrenia. Br J Psychiatry 1986, 148:554–559.PubMedCrossRefGoogle Scholar
  17. 17.
    Meltzer HY, Okayli G: Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. Am J Psychiatry 1995, 152:183–190.PubMedGoogle Scholar
  18. 18.
    Ciompi L: Late suicide in former mental patients. Psychiatr Clin (Basel) 1976, 9:59–63.Google Scholar
  19. 19.
    Winokur G, Rsuang M: The Iowa 500: suicide in mania, depression, and schizophrenia. Am J Psychiatry 1975, 132:650–651.PubMedGoogle Scholar
  20. 20.
    Drake RE, Ehrlich J: Suicide attempts associated with akathisia. Am J Psychiatry 1985, 142:499–501.PubMedGoogle Scholar
  21. 21.
    Shear MK, Frances A, Weiden P: Suicide associated with akathisia and depot fluphenazine treatment. Suicide 1983, 3:235–236.Google Scholar
  22. 22.
    Siris SG: Suicide and schizophrenia. J Psychopharmacol 2001, 15:127–135. ood articlePubMedGoogle Scholar
  23. 23.
    Tran PV, Hamilton SH, Kuntz AJ, et al.: Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacolog 1997, 17:407–418.CrossRefGoogle Scholar
  24. 24.
    Khan A, Khan SR, Lenthal RM, Brown WA: Symptom reduction and suicide risk among patients treated with placebo in antipsychotic clinical trials: an analysis of the Food and Drug Administration database. Am J Psychiatry 2001, 158:1449–1454. A good article.PubMedCrossRefGoogle Scholar
  25. 25.
    Reid WH, Mason M, Hogan T: Suicide prevention effects associated with clozapine therapy in schizophrenia and schizoaffective disorder. Psychiatr Serv 1998, 49:1029–1033.PubMedGoogle Scholar
  26. 26.
    Spivak B, Roitman S, Vered Y, et al.: Diminished suicidal and aggressive behavior high plasma norepinephrine levels and serum triglyceride levels in chronic neuroleptic-resistant schizophrenic patients maintained on clozapine. Clin Neuropharmacol 1998, 21:245–250.PubMedGoogle Scholar
  27. 27.
    Walker AM, Lanaza LL, Arellano F, Rothman KJ: Mortality in current and former users of clozapine. Epidemiology 1997, 8:671–677.PubMedCrossRefGoogle Scholar
  28. 28.
    Munro J, O’Sullivan D, Andrews C, et al.: Active monitoring of 12,760 clozapine recipients in the UK and Ireland: beyond pharmacovigilance. Brit J Psychiatry 1999, 175:576–580.CrossRefGoogle Scholar
  29. 29.
    Sernyak MJ, Desai R, Stolar M, Rosenheck R: Impact of clozapine on completed suicide. Am J Psychiatry 2001, 158:931–937.PubMedGoogle Scholar

Copyright information

© Current Science Inc 2002

Authors and Affiliations

  • Herbert Y. Meltzer
    • 1
  1. 1.Psychiatric Hospital of VanderbiltNashvilleUSA

Personalised recommendations